Drugs

Article	Citations
Prevention and Treatment of Monkeypox	352
BNT162b2 mRNA COVID-19 Vaccine: First Approval	249
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	243
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	213
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	212
Inclisiran: First Approval	201
Lumasiran: First Approval	184
Nirmatrelvir Plus Ritonavir: First Approval	176
Remdesivir: First Approval	175
Acute Pancreatitis: Diagnosis and Treatment	164
Casimersen: First Approval	161
Aducanumab: First Approval	146
Sotorasib: First Approval	128
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	116
TRPV1-Targeted Drugs in Development for Human Pain Conditions	113
Risdiplam: First Approval	111
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	109
Setmelanotide: First Approval	108
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	108
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	98
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	98
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer	92
Belantamab Mafodotin: First Approval	92
Bulevirtide: First Approval	89
Nivolumab Plus Relatlimab: First Approval	87

Orelabrutinib: First Approval	86
REGN-EB3: First Approval	81
Deucravacitinib: First Approval	80
Amivantamab: First Approval	79
Lonafarnib: First Approval	79
Remimazolam: A Review in Procedural Sedation	78
Fabry Disease: The Current Treatment Landscape	78
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	75
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review	74
Decitabine/Cedazuridine: First Approval	74
Belzutifan: First Approval	73
Faricimab: First Approval	73
Abrocitinib: First Approval	70
Pralsetinib: First Approval	70
Savolitinib: First Approval	68
Vutrisiran: First Approval	68
Disitamab Vedotin: First Approval	66
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	65
Tisotumab Vedotin: First Approval	65
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	64
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	63
Molnupiravir: First Approval	61
Cadonilimab: First Approval	61
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	61
Trilaciclib: First Approval	60
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	60
Current Status of Clinical Trials on Tau Immunotherapies	59
Telitacicept: First Approval	58
Casirivimab/Imdevimab: First Approval	58
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics	58
Infigratinib: First Approval	57
Targeting AMPK by Statins: A Potential Therapeutic Approach	57
Contezolid: First Approval	57
Loncastuximab Tesirine: First Approval	57
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	56
Efgartigimod: First Approval	56
Tebentafusp: First Approval	55
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals	54
Envafolimab: First Approval	54
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	54
Lecanemab: First Approval	54
Ocrelizumab: A Review in Multiple Sclerosis	54
Dostarlimab: First Approval	53
Tirzepatide: First Approval	53
Pegcetacoplan: First Approval	51
Umbralisib: First Approval	51
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	50
Filgotinib: First Approval	50
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update	50
Naxitamab: First Approval	49

Daprodustat: First Approval	48
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	48
Nirsevimab: First Approval	48
Anifrolumab: First Approval	47
Fuzuloparib: First Approval	47
Donafenib: First Approval	47
Odevixibat: First Approval	47
Tremelimumab: First Approval	47
Mavacamten: First Approval	46
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents	45
Givosiran: A Review in Acute Hepatic Porphyria	45
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review	45
Therapeutic Options in Hereditary Optic Neuropathies	45
Teclistamab: First Approval	45
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists	44
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review	44
Delandistrogene Moxeparvovec: First Approval	44
Regdanvimab: First Approval	44
Mirvetuximab Soravtansine: First Approval	44
Spesolimab: First Approval	43
Lazertinib: First Approval	43
Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon	43
Adagrasib: First Approval	42
Androgenetic Alopecia: Therapy Update	42
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics	42
Voclosporin: First Approval	42
Tezepelumab: First Approval	42
Valoctocogene Roxaparvovec: First Approval	41
Sotrovimab: First Approval	41
Avacopan: First Approval	40
Pamiparib: First Approval	40
Mosunetuzumab: First Approval	40
Etranacogene Dezaparvovec: First Approval	39
Vericiguat: First Approval	39
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes	38
Daridorexant: First Approval	38
Pacritinib: First Approval	38
Melphalan Flufenamide (Melflufen): First Approval	38
Asciminib: First Approval	38
Finerenone: First Approval	38
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	37
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	37
Evinacumab: First Approval	37
Tixagevimab + Cilgavimab: First Approval	36
Olverembatinib: First Approval	36
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	36
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy	36
Ansuvimab: First Approval	36
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents	36
Ibrexafungerp: First Approval	36
Ozoralizumab: First Approval	35
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?	35
Tofersen: First Approval	34
Margetuximab: First Approval	34
Futibatinib: First Approval	34
Mobocertinib: First Approval	34
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	33
Maralixibat: First Approval	33
Atogepant: First Approval	33
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease	33
Tapinarof Cream 1%: First Approval	32
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa	31
Oliceridine: First Approval	31
Lenacapavir: First Approval	31
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)	31
Difelikefalin: First Approval	31
Belumosudil: First Approval	30
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies	30
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?	30
Post-Thoracotomy Pain: Current Strategies for Prevention and Treatment	30
Oteseconazole: First Approval	29
The Potential Role of Clinical Metagenomics in Infectious Diseases: Therapeutic Perspectives	29
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC	29
Nemolizumab: First Approval	29
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	29
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry	29
Tralokinumab: First Approval	28
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars	28
Omaveloxolone: First Approval	28
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	28

Ganaxolone: First Approval	28
Secukinumab: A Review in Psoriatic Arthritis	27
Hetrombopag: First Approval	27
Ocular Toxicity of Targeted Anticancer Agents	27
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	27
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review	26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	26
Pimitespib: First Approval	26
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density	26
Enarodustat: First Approval	26
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis	26
New Agents in Development for Sepsis: Any Reason for Hope?	26
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	26
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation	25
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	25
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review	25